A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

(Reuters) -Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner companies.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. A second test of the drug, itepekimab, was successful.

A second test of the drug, itepekimab ... Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials." Regeneron Pharmaceuticals. "Dupixent® (dupilumab) Approved in ...